Literature DB >> 11515423

Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy.

K Hellmann, E O Field.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 11515423

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

1.  Effect of ICRF 159 on immune responses.

Authors:  K Hellmann
Journal:  Proc R Soc Med       Date:  1972-03

2.  Combined treatment of the Walker tumour with radiotherapy and ICRF 159.

Authors:  K Norpoth; A Schaphaus; H Ziegler; U Witting
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1974

3.  Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic.

Authors:  A J Salsbury; K Burrage; K Hellmann
Journal:  Br Med J       Date:  1970-11-07

4.  Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.

Authors:  C L Vogel; E Gorowski; E Davila; M Eisenberger; J Kosinski; R P Agarwal; N Savaraj
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1989-03

6.  The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.

Authors:  R H Wheeler; D J Clauw; R B Natale; R W Ruddon
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

7.  Is ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] unusually reactive for an imide?

Authors:  J M Sisco; V J Stella
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

8.  ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.

Authors:  C J Kovacs; M J Evans; L L Schenken; D R Burholt
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

9.  Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.

Authors:  I W Taylor; N M Bleehen
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

10.  ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.

Authors:  C J Kovacs; M J Evans; D R Burholt; L L Schenken
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.